About Contact Us Careers
Sign In

Aplastic Anemia Treatment Market Size & Share, by Treatment Type (Stem Cell Therapy, Blood Transfusion, Drug Therapy); Disease Type (Acquired Aplastic Anemia, Inherited Aplastic Anemia); Route of Administration (Intravenous, Oral); End-user (Hospitals, Specialty Clinics, Research Institutes) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 3799
  • Published Date: Mar 31, 2023
  • Report Format: PDF, PPT

Companies Dominating the Aplastic Anemia Treatment Landscape

top-features-companies
    • F. Hoffmann-La Roche Ltd.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Eisai Co., Ltd.
    • Allergan, Inc.
    • TauRx Therapeutics Ltd.
    • AbbVie Inc.
    • Novartis AG
    • Siemens Healthcare GmbH
    • Pfizer, Inc.
    • Bristol-Myers Squibb Company
    • Bayers AG
Browse Key Market Insights with Data Illustration:

In the News

  • Sandoz announced the acquisition of GSK's cephalosporin antibiotic business to expand its collection of antimicrobials. This acquisition allows Sandoz to increase its portfolio of antibiotics, which is beneficial for both Sandoz and the patients they serve. The acquisition also gives Sandoz access to GSK's patented technology, which will help them stay competitive in the industry.

  • In Europe, the European Commission approved the consolidation of Mylan and Upjohn between Pfizer and Mylan. Combining Mylan's generics market presence with Pfizer's branded market presence will enable the companies to create a new global healthcare leader.


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 3799
  • Published Date: Mar 31, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The increasing number of people being diagnosed with aplastic anemia, improved access to healthcare, and the availability of new and improved treatment options are the major factors expected to drive the market growth.

The market is anticipated to attain a CAGR of 5% over the forecast period, i.e., 2023-2035.

High cost of treatment, the side effects associated with the treatment, limited availability of suitable donors estimated to be the growth hindering factors for the market expansion.

The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are profiled by Research Nester are F. Hoffmann-La Roche Ltd., Eisai Co., Ltd., Allergan, Inc., TauRx Therapeutics Ltd., AbbVie Inc., Novartis AG, Siemens Healthcare GmbH, Pfizer, Inc., Bristol-Myers Squibb Company, Bayers AG, and other key market players.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

Ans: The market is segmented by treatment type, disease type, route of administration, end user and by region.

The stem cell therapy segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying